Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
This study has been completed.
Study NCT00421733   Information provided by Abbott
First Received: January 10, 2007   Last Updated: July 13, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetic Nephropathy
Additional conditions recognized in this trial
Albuminuria
Diabetic Nephropathies
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency, Chronic
More general conditions related to this trial
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Kidney Failure
Proteinuria
Renal Insufficiency
Signs and Symptoms
Urination Disorders
Urologic Diseases
Urological Manifestations
Interventions listed in this trial
Zemplar (paricalcitol ) capsules
Zemplar (paricalcitol) capsules
Placebo
Additional drug interventions recognized in this trial
Ergocalciferols
More general drug interventions related to this trial
Bone Density Conservation Agents
Growth Substances
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Vitamins
Sponsors listed in this trial
Abbott


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services